Lake Street Capital Cuts Femasys (NASDAQ:FEMY) Price Target to $10.00

Femasys (NASDAQ:FEMY) had its price objective cut by investment analysts at Lake Street Capital from $30.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price target would indicate a potential upside of 352.28% from the company’s current price.

A number of other research analysts also recently weighed in on FEMY. Maxim Group lowered their price target on Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday. Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Trading Up 2.4%

Shares of Femasys stock traded up $0.05 during trading on Tuesday, hitting $2.21. The stock had a trading volume of 111,027 shares, compared to its average volume of 65,580. The stock has a 50 day simple moving average of $3.53 and a 200 day simple moving average of $7.21. The company has a market capitalization of $6.68 million, a PE ratio of -0.63 and a beta of -2.08. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. Femasys has a 1 year low of $2.02 and a 1 year high of $22.20.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 208.04%. The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million.

Insider Activity

In other news, CFO Dov Elefant purchased 15,625 shares of Femasys stock in a transaction dated Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer directly owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $3.20 per share, with a total value of $50,000.00. Following the purchase, the chief executive officer owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 38,750 shares of company stock worth $124,000. Insiders own 7.75% of the company’s stock.

Institutional Investors Weigh In On Femasys

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Femasys by 50.8% during the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after buying an additional 131,052 shares during the last quarter. Banco BTG Pactual S.A. acquired a new stake in shares of Femasys in the fourth quarter valued at about $88,000. Jane Street Group LLC bought a new position in shares of Femasys during the fourth quarter worth about $62,000. State Street Corp lifted its stake in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares during the period. Finally, Cetera Investment Advisers bought a new stake in Femasys in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.